M
MatriSys Bioscience
Clinical stage specialty biopharmaceutical company
About MatriSys Bioscience
MatriSys Bioscience is a biopharmaceutical startup that operates in the healthcare sector, specifically in the field of dermatology. The company is focused on the discovery and clinical development of a new class of biopharmaceuticals aimed at transforming the treatment of chronic skin diseases. Their innovative technology platform identifies beneficial bacteria derived from healthy human skin. This could potentially provide a solution for millions of children and adults who suffer from hard-to-treat chronic skin conditions.
Read full description
MatriSys Bioscience's business model revolves around the development of this technology and the subsequent commercialization of the resulting treatments. The company's primary clients are patients suffering from chronic skin diseases, a group that represents a significant portion of the population. The company aims to fill a gap in the market by reducing the reliance on steroids, immunosuppressants, and antibiotics in dermatological treatments, which are often associated with side effects and can contribute to antibiotic resistance.
The company generates revenue by developing and selling these novel treatments. As a biopharmaceutical company, MatriSys Bioscience also likely relies on funding from investors, grants, and partnerships with larger pharmaceutical companies to support its research and development efforts.
In summary, MatriSys Bioscience is a promising startup in the biopharmaceutical industry, using innovative technology to develop new treatments for chronic skin diseases, aiming to improve patient outcomes and meet a significant unmet medical need.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Diego, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 57.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Dermatology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning MatriSys Bioscience.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2022 | $62M | $247M | Undisclosed | ↗ |
| EARLY VCOther financing | Mar 2021 | $3M | $12M | Undisclosed | — |
Growth signals
Latest recorded traffic for MatriSys Bioscience is 710 monthly website visits, up 20.3% over the last three months. MatriSys Bioscience's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Tech Coast Angels- PCPrimer Capital
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MatriSys Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MatriSys Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.